ST JOHN HOSPITAL & MEDICAL CENTER
- Type
- Teaching hospital
- Where
- Detroit, MI
- Medicare CCN
- 230165
- Received
- $595,106 in 126 records, 2021 ($78,001 general, $517,105 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 8 | $78,001 |
| 2021 | Research payment | 118 | $517,105 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | 1 | $186,733 | 2021 |
| Medtronic, Inc. | 30 | $85,330 | 2021 |
| Genetesis, Inc. | 7 | $75,490 | 2021 |
| AngioDynamics, Inc. | 2 | $73,000 | 2021 |
| ViiV Healthcare Company | 15 | $46,191 | 2021 |
| Abbott Laboratories | 18 | $41,931 | 2021 |
| Gilead Sciences, Inc. | 11 | $18,762 | 2021 |
| Amgen Inc. | 1 | $15,062 | 2021 |
| Penumbra, Inc. | 10 | $14,557 | 2021 |
| Bard Peripheral Vascular, Inc. | 1 | $10,000 | 2021 |
| Alexion Pharmaceuticals, Inc. | 2 | $6,064 | 2021 |
| PFIZER INC. | 1 | $4,750 | 2021 |
| RedHill Biopharma Inc. | 4 | $3,684 | 2021 |
| Biogen, Inc. | 1 | $2,203 | 2021 |
| Stryker Corporation | 2 | $2,106 | 2021 |
| Merge Healthcare Incorporated | 3 | $1,894 | 2021 |
| Celgene Corporation | 1 | $1,830 | 2021 |
| Cardiovascular Systems Inc. | 3 | $1,618 | 2021 |
| Pharmacyclics LLC, an AbbVie Company | 10 | $1,580 | 2021 |
| Boston Scientific Corporation | 1 | $1,300 | 2021 |
| Janssen Pharmaceuticals, Inc | 1 | $1,000 | 2021 |
| Eli Lilly and Company | 1 | $16 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 118 | $517,105 |
| Education | 2 | $73,000 |
| Long term medical supply or device loan | 2 | $2,106 |
| Food and Beverage | 3 | $1,894 |
| Space rental or facility fees (teaching hospital only) | 1 | $1,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | AngioDynamics, Inc. | $60,000 | Education | In-kind items and services | NanoKnife Device, Oncology Surgery | 2021 | |
| 2021-12-31 | AngioDynamics, Inc. | $13,000 | Education | In-kind items and services | Solero Device, Oncology | 2021 | |
| 2021-12-22 | Gilead Sciences, Inc. | $883 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2021 | |
| 2021-12-16 | Medtronic, Inc. | $262 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-12-16 | Medtronic, Inc. | $262 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-12-09 | Alexion Pharmaceuticals, Inc. | $3,604 | Research payment | Cash or cash equivalent | An Observational Disease and Clinical Outcomes Registry of Patients With Lysosomal Acid Lipase (LAL) Deficiency | 2021 | |
| 2021-12-07 | Genetesis, Inc. | $11,760 | Research payment | Cash or cash equivalent | ACCMED | 2021 | |
| 2021-11-29 | Genetesis, Inc. | $11,130 | Research payment | Cash or cash equivalent | ACCMED | 2021 | |
| 2021-11-26 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-11-17 | Penumbra, Inc. | $1,000 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2021 |
| 2021-11-17 | Gilead Sciences, Inc. | $963 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2021 | |
| 2021-11-17 | Penumbra, Inc. | $200 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2021 |
| 2021-11-17 | Penumbra, Inc. | $200 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2021 |
| 2021-11-15 | Boston Scientific Corporation | $1,300 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | SMART MULTI SITE PACING STUDY | 2021 |
| 2021-11-10 | Abbott Laboratories | $11,100 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-11-10 | Penumbra, Inc. | $1,000 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2021 |
| 2021-11-01 | Medtronic, Inc. | $1,607 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-11-01 | Medtronic, Inc. | $1,607 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-10-27 | Genetesis, Inc. | $11,950 | Research payment | Cash or cash equivalent | ACCMED | 2021 | |
| 2021-10-26 | Penumbra, Inc. | $1,000 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2021 |
| 2021-10-25 | Stryker Corporation | $1,053 | Long term medical supply or device loan | In-kind items and services | ISOFLEX LAL Device, PATIENT HANDLING - PH | 2021 | |
| 2021-10-25 | Stryker Corporation | $1,053 | Long term medical supply or device loan | In-kind items and services | ISOFLEX LAL Device, PATIENT HANDLING - PH | 2021 | |
| 2021-10-20 | Medtronic, Inc. | $4,815 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2021 |
| 2021-10-20 | Medtronic, Inc. | $4,815 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2021 |
| 2021-10-20 | Gilead Sciences, Inc. | $1,179 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2021 | |
| 2021-10-15 | ViiV Healthcare Company | $1,431 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-10-07 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-10-07 | Penumbra, Inc. | $200 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2021 |
| 2021-10-07 | ViiV Healthcare Company | $33 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-10-06 | Abbott Laboratories | $9,000 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-10-05 | Gilead Sciences, Inc. | $5,760 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2021 | |
| 2021-10-04 | ViiV Healthcare Company | $500 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-09-29 | Abbott Laboratories | $45 | Research payment | In-kind items and services | ESPRIT Device, Vascular | LIFE-BTK | 2021 |
| 2021-09-22 | Gilead Sciences, Inc. | $1,785 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2021 | |
| 2021-09-21 | ViiV Healthcare Company | $25 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-09-16 | Pharmacyclics LLC, an AbbVie Company | $158 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-09-13 | Medtronic, Inc. | $2,390 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-09-13 | Medtronic, Inc. | $2,390 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-09-09 | Abbott Laboratories | $250 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-08-30 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-08-30 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-08-27 | Genetesis, Inc. | $10,630 | Research payment | Cash or cash equivalent | ACCMED | 2021 | |
| 2021-08-26 | Merge Healthcare Incorporated | $1,174 | Food and Beverage (4 payments) | Cash or cash equivalent | PACS Device, Medical Imaging | 2021 | |
| 2021-08-23 | ViiV Healthcare Company | $4,885 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-08-23 | Janssen Pharmaceuticals, Inc | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-08-18 | Abbott Laboratories | $8,540 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-08-11 | Medtronic, Inc. | $3,418 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2021 |
| 2021-08-11 | Medtronic, Inc. | $3,418 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2021 |
| 2021-07-29 | Medtronic, Inc. | $3,239 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-07-29 | Medtronic, Inc. | $3,239 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-07-29 | Alexion Pharmaceuticals, Inc. | $2,460 | Research payment | Cash or cash equivalent | An Observational Disease and Clinical Outcomes Registry of Patients With Lysosomal Acid Lipase (LAL) Deficiency | 2021 | |
| 2021-07-28 | Penumbra, Inc. | $8,000 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2021 |
| 2021-07-27 | ViiV Healthcare Company | $3,338 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-07-15 | Pharmacyclics LLC, an AbbVie Company | $158 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-07-15 | Pharmacyclics LLC, an AbbVie Company | $158 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-07-01 | Genetesis, Inc. | $10,060 | Research payment | Cash or cash equivalent | ACCMED | 2021 | |
| 2021-06-30 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-06-23 | Gilead Sciences, Inc. | $1,536 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2021 | |
| 2021-06-21 | Merge Healthcare Incorporated | $219 | Food and Beverage (4 payments) | Cash or cash equivalent | PACS Device, Medical Imaging | 2021 | |
| 2021-06-17 | Penumbra, Inc. | $390 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | CHEETAH | 2021 |
| 2021-06-15 | Pharmacyclics LLC, an AbbVie Company | $158 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-06-14 | ViiV Healthcare Company | $4,410 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-06-04 | Medtronic, Inc. | $600 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-06-04 | Medtronic, Inc. | $600 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-05-26 | Abbott Laboratories | $1,650 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-05-25 | Abbott Laboratories | $1,239 | Research payment | Cash or cash equivalent | Absorb GT1 Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2021 |
| 2021-05-21 | RedHill Biopharma Inc. | $1,463 | Research payment | Cash or cash equivalent | Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled P | 2021 | |
| 2021-05-21 | RedHill Biopharma Inc. | $1,330 | Research payment | Cash or cash equivalent | Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled P | 2021 | |
| 2021-05-21 | RedHill Biopharma Inc. | $665 | Research payment | Cash or cash equivalent | Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled P | 2021 | |
| 2021-05-21 | RedHill Biopharma Inc. | $226 | Research payment | Cash or cash equivalent | Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled P | 2021 | |
| 2021-05-20 | Merge Healthcare Incorporated | $500 | Food and Beverage | Cash or cash equivalent | radiology Device, Medical Imaging | 2021 | |
| 2021-05-19 | Gilead Sciences, Inc. | $963 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2021 | |
| 2021-05-19 | Medtronic, Inc. | $600 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-05-19 | Medtronic, Inc. | $600 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-05-18 | Pharmacyclics LLC, an AbbVie Company | $158 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-05-18 | Pharmacyclics LLC, an AbbVie Company | $158 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-05-18 | Eli Lilly and Company | $16 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATIO | 2021 | |
| 2021-05-17 | Medtronic, Inc. | $1,407 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-05-17 | Medtronic, Inc. | $1,407 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-05-14 | ViiV Healthcare Company | $1,440 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-05-13 | Medtronic, Inc. | $15,382 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2021 |
| 2021-05-13 | Medtronic, Inc. | $15,382 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2021 |
| 2021-05-13 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | Abbott Vascular / XIENCE | 2021 |
| 2021-05-08 | PFIZER INC. | $4,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUD | 2021 |
| 2021-05-06 | Abbott Laboratories | $250 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | Abbott Vascular / XIENCE | 2021 |
| 2021-05-03 | Genetesis, Inc. | $8,560 | Research payment | Cash or cash equivalent | ACCMED | 2021 | |
| 2021-04-26 | Gilead Sciences, Inc. | $1,832 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2021 | |
| 2021-04-22 | Abbott Laboratories | $2,000 | Research payment | Cash or cash equivalent | Quadra Assura CRT Defibrillator Device, Cardiac Rhythm Management | St. Jude Medical Product Longevity and Performance (SCORE) Registry | 2021 |
| 2021-04-15 | Pharmacyclics LLC, an AbbVie Company | $158 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-04-08 | ViiV Healthcare Company | $6,335 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-04-08 | Penumbra, Inc. | $390 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | CHEETAH | 2021 |
| 2021-04-03 | Abbott Laboratories | $332 | Research payment | In-kind items and services | Device, Cardiac Rhythm Management | Leadless II | 2021 |
| 2021-04-01 | JAZZ PHARMACEUTICALS INC. | $186,733 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2021 |
| 2021-03-24 | ViiV Healthcare Company | $101 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-03-24 | ViiV Healthcare Company | $93 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-03-23 | Abbott Laboratories | $600 | Research payment | Cash or cash equivalent | Absorb GT1 Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2021 |
| 2021-03-17 | Gilead Sciences, Inc. | $2,015 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2021 | |
| 2021-03-16 | Medtronic, Inc. | $1,516 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2021 | |
| 2021-03-16 | Medtronic, Inc. | $1,516 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2021 | |
| 2021-03-12 | Genetesis, Inc. | $11,400 | Research payment | Cash or cash equivalent | ACCMED | 2021 | |
| 2021-03-12 | ViiV Healthcare Company | $6,687 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-03-04 | Medtronic, Inc. | $212 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-03-04 | Medtronic, Inc. | $212 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-02-25 | ViiV Healthcare Company | $9,908 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-02-18 | Penumbra, Inc. | $2,177 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | CHEETAH | 2021 |
| 2021-02-17 | Gilead Sciences, Inc. | $963 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2021 | |
| 2021-02-12 | Bard Peripheral Vascular, Inc. | $10,000 | Research payment | Cash or cash equivalent | ULTRASCORE Device, BD Interventional Surgery | UltraScore | 2021 |
| 2021-02-10 | Medtronic, Inc. | $2,714 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-02-10 | Medtronic, Inc. | $2,714 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2021 |
| 2021-02-10 | Celgene Corporation | $1,830 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Connect MDS/AML | 2021 |
| 2021-02-10 | Abbott Laboratories | $1,275 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-02-10 | Cardiovascular Systems Inc. | $325 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2021 |
| 2021-02-09 | Medtronic, Inc. | $4,000 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-02-09 | Medtronic, Inc. | $4,000 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-02-09 | Pharmacyclics LLC, an AbbVie Company | $158 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-02-09 | Pharmacyclics LLC, an AbbVie Company | $158 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-02-01 | ViiV Healthcare Company | $5,000 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-02-01 | ViiV Healthcare Company | $2,000 | Research payment | Cash or cash equivalent | A PHASE IIIB, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL-GRO | 2021 | |
| 2021-01-29 | Abbott Laboratories | $2,500 | Research payment | Cash or cash equivalent | Dragonfly OCT Device, Vascular | Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II) | 2021 |
| 2021-01-26 | Abbott Laboratories | $400 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | Abbott Vascular / XIENCE | 2021 |
| 2021-01-20 | Amgen Inc. | $15,062 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States | 2021 |
| 2021-01-20 | Gilead Sciences, Inc. | $883 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2021 | |
| 2021-01-14 | Pharmacyclics LLC, an AbbVie Company | $158 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-01-12 | Cardiovascular Systems Inc. | $500 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2021 |
| 2021-01-08 | Cardiovascular Systems Inc. | $793 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2021 |
| 2021-01-01 | Biogen, Inc. | $2,203 | Research payment | Cash or cash equivalent | Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Follo | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Detroit, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 638,530 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 639,111 | 1,793,561 | 10,077,331 |
| Median age B01002 | 35.2 | 37.9 | 40.2 |
| Under 18 B01001 | 24.8% | 23.6% | 21.2% |
| 65 and over B01001 | 15.1% | 16.6% | 18.6% |
| Households B11001 | 257,998 | 700,591 | 4,076,369 |
| Foreign born B05002 | 6.6% | 10.3% | 7.2% |
| Median household income B19013 | $39,938 | $60,539 | $72,875 |
| Median family income B19113 | $49,398 | $79,522 | $93,357 |
| Per capita income B19301 | $24,594 | $34,906 | $40,735 |
| Poverty rate B17001 | 32.7% | 20.8% | 13.2% |
| Unemployment rate B23025 | 14.0% | 8.7% | 5.7% |
| Civilian labor force B23025 | 268,955 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 24.8 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 18.1% | 27.6% | 32.4% |
| Housing units B25001 | 329,393 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 50.3% | 64.8% | 73.2% |
| Renters B25003 | 49.7% | 35.2% | 26.8% |
| Median home value B25077 | $83,900 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,074 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 10.8% | 47.9% | 72.4% |
| Black B03002 | 75.0% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 8.3% | 6.9% | 5.9% |
| Asian B03002 | 1.7% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.
Comments